Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Alzheimer’s disease (AD), as a neurodegenerative disorder, usually develops slowly but gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is recognized by WHO as a public health priority. Being a multifactorial disease, the origins of AD are not satisfactorily unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Ailioaie, Laura Marinela, Ailioaie, Constantin, Litscher, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054386/
https://www.ncbi.nlm.nih.gov/pubmed/36986776
http://dx.doi.org/10.3390/pharmaceutics15030916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054386/
https://www.ncbi.nlm.nih.gov/pubmed/36986776
http://dx.doi.org/10.3390/pharmaceutics15030916

Ejemplares similares